Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 1.410
-0.055 (-3.75%)
May 6, 2026, 5:22 PM CET
STO:NEWBRY Revenue
Newbury Pharmaceuticals AB had revenue of 8.45M SEK in the quarter ending February 28, 2026, a decrease of -32.01%. This brings the company's revenue in the last twelve months to 32.78M, down -20.99% year-over-year. In the fiscal year ending August 31, 2025, Newbury Pharmaceuticals AB had annual revenue of 31.57M, down -14.27%.
Revenue (ttm)
32.78M
Revenue Growth
-20.99%
P/S Ratio
1.36
Revenue / Employee
4.68M
Employees
7
Market Cap
44.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 31.57M | -5.26M | -14.27% |
| Aug 31, 2024 | 36.83M | 26.56M | 258.75% |
| Aug 31, 2023 | 10.27M | 4.75M | 86.11% |
| Aug 31, 2022 | 5.52M | 2.43M | 78.73% |
| Aug 31, 2021 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 54.32M |
| Enzymatica AB | 53.06M |
| Orexo AB | 17.80M |
| Moberg Pharma AB | 13.54M |
| Klaria Pharma Holding AB (publ.) | 8.99M |
| Enorama Pharma AB | 2.74M |